CSPC PHARMA(01093): The Phase II clinical trial of SYH2069 injection for the treatment of adults with type 2 diabetes has officially been initiated at the first research center in China.

CSPC PHARMA (01093) announced that the Phase II clinical trial (SYH2069-003) of SYH2069 injection ("the Product"), developed by the Group for the treatment of adults with type 2 diabetes, has officially been initiated at the first research center in China. The Product is a novel fatty acid-modified peptide-based long-acting glucagon-like peptide-1 receptor ("GLP-1R") and glucose-dependent insulinotropic polypeptide receptor ("GIPR") dual-target dual-biased agonist. It is designed to selectively activate GLP-1R and GIPR to promote insulin secretion in a glucose-dependent manner, and is expected to synergistically exert glucose-lowering and weight-loss effects by suppressing appetite, delaying gastric emptying, increasing satiety, and reducing caloric intake. In addition, by selectively activating the cyclic adenosine monophosphate (cAMP) signaling pathway downstream of GLP-1R and GIPR, the Product can avoid receptor internalization and desensitization caused by -arrestin recruitment, thereby enhancing its activity and prolonging the duration of efficacy. Preclinical studies have shown that the Product demonstrates favorable target activity and a controllable safety profile. In December 2025, the Group obtained the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration of the People's Republic of China ("NMPA") for the Product for the overweight or obesity indication, and initiated the related Phase I clinical trial after approval; these trials preliminarily demonstrated the safety, tolerability, and pharmacokinetic and pharmacodynamic characteristics of the Product in humans. Subsequently, in April 2026, the Group obtained the Drug Clinical Trial Approval Notice issued by the NMPA for the Product for the type 2 diabetes indication, and the Product is expected to demonstrate durable glucose-lowering effects and clinical benefits in Chinese adults with type 2 diabetes. The clinical trial initiated this time is a multicenter, randomized, double-blind, placebo- and active-controlled, parallel-group Phase II clinical trial, designed to evaluate the efficacy and safety of the Product under different dosing regimens in adults with type 2 diabetes. Participant recruitment and screening for this Phase II clinical trial are actively underway.